My Treatment Approach: Individualizing Treatment Selection and Sequencing in Platinum-Resistant Ovarian Cancer

Rachel N. Grisham, MD, of Memorial Sloan Kettering Cancer Center in New York, New York, and Ritu Salani, MD, MBA, of the David Geffen School of Medicine at UCLA in Los Angeles, California, discuss how they individualize treatment selection and sequencing for patients with platinum-resistant ovarian cancer, covering biomarker testing, the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel, day-to-day management of adverse events, and two patient cases.